| JaLCDOI | 10.18926/AMO/62394 |
|---|---|
| FullText URL | 75_4_431.pdf |
| Author | Kunitomi, Toshiki| Nasu, Junichirou| Minami, Daisuke| Iwamoto, Takayuki| Nishie, Hiroyuki| Saito, Shinya| Fujiwara, Toshiyoshi| Matsuoka, Junji| |
| Abstract | This study aimed to evaluate whether there are differences in the attitudes and practices of cancer pain manage-ment between medical oncologists and palliative care physicians. An online nationwide survey was used to collect responses from board-certified medical oncologists and palliative care physicians in Japan. The survey questionnaire comprised 30 questions. The differences in responses between medical oncologists and palliative care physicians were examined. Out of the 1,227 questionnaires sent, 522 (42.5%) were returned. After apply-ing the exclusion criteria, 445 questionnaires (medical oncologists: n = 283; palliative care physicians: n = 162) were retained for analysis. Among the questions about potential barriers to optimal cancer pain man-agement, both medical oncologists and palliative care physicians considered the reluctance of patients to take opioids due to fear of adverse effects as the greatest barrier. Significantly different ratings between medical oncologists and palliative care physicians were observed on 5 of the 8 questions in this area. Significantly differ-ent ratings were observed for all questions concerning pain specialists and their knowledge. For effective cancer pain management, it is important to account for differences in attitudes and practice between medical oncolo-gists and palliative care physicians. |
| Keywords | cancer pain management opioid medical oncologist palliative care physician barriers |
| Amo Type | Original Article |
| Publication Title | Acta Medica Okayama |
| Published Date | 2021-08 |
| Volume | volume75 |
| Issue | issue4 |
| Publisher | Okayama University Medical School |
| Start Page | 431 |
| End Page | 437 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2021 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 34511609 |
| Web of Science KeyUT | 000697944600004 |
| NAID | 120007146037 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Katayama, Hideki| Tabata, Masahiro| Kubo, Toshio| Kiura, Katsuyuki| Matsuoka, Junji| Maeda, Yoshinobu| |
| Keywords | Weekend chemotherapy Outpatient Social burden Cancer patient |
| Published Date | 2020-07-04 |
| Publication Title | Supportive Care in Cancer |
| Volume | volume29 |
| Publisher | Springer |
| Start Page | 1287 |
| End Page | 1297 |
| ISSN | 0941-4355 |
| NCID | AA10996793 |
| Content Type | Journal Article |
| language | English |
| OAI-PMH Set | 岡山大学 |
| File Version | publisher |
| PubMed ID | 32621265 |
| DOI | 10.1007/s00520-020-05575-x |
| Web of Science KeyUT | 000545922600001 |
| Related Url | isVersionOf https://doi.org/10.1007/s00520-020-05575-x |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Takahashi, Yuko| Iwamoto, Takayuki| Suzuki, Yoko| Kajiwara, Yukiko| Hatono, Minami| Tsukioki, Takahiro| Kawada, Kengo| Kochi, Mariko| Ikeda, Hirokuni| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| Toyooka, Shinichi| |
| Keywords | Gene expression Hormone receptor positive Residual tumor burden Targeted therapy Triple negative |
| Published Date | 2020-04 |
| Publication Title | Clinical Breast Cancer |
| Volume | volume20 |
| Issue | issue2 |
| Publisher | Elsevier |
| Start Page | 117 |
| End Page | 124 |
| ISSN | 1526-8209 |
| NCID | AA11694891 |
| Content Type | Journal Article |
| language | English |
| OAI-PMH Set | 岡山大学 |
| File Version | author |
| PubMed ID | 31570267 |
| DOI | 10.1016/j.clbc.2019.07.001 |
| Web of Science KeyUT | 000529805200021 |
| Related Url | isVersionOf https://doi.org/10.1016/j.clbc.2019.07.001 |
| FullText URL | BreastCancer_24_4_593.pdf BreastCancer_24_4_593_tbl_fig.pdf |
|---|---|
| Author | Saiga, Miho| Taira, Naruto| Kimata, Yoshihiro| Watanabe, Satoko| Mukai, Yuko| Shimozuma, Kojiro| Mizoo, Taeko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| |
| Keywords | BREAST-Q Breast cancer Breast reconstruction Health-related quality of life Satisfaction |
| Published Date | 2017-03 |
| Publication Title | Breast Cancer |
| Volume | volume24 |
| Issue | issue2 |
| Publisher | Japanese Breast Cancer Society |
| Start Page | 288 |
| End Page | 298 |
| ISSN | 1340-6868 |
| NCID | AA1103354X |
| Content Type | Journal Article |
| language | English |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja |
| File Version | author |
| PubMed ID | 27179527 |
| DOI | 10.1007/s12282-016-0703-6 |
| Web of Science KeyUT | 000395524900012 |
| Related Url | isVerionOf https://doi.org/10.1007/s12282-016-0703-6 |
| JaLCDOI | 10.18926/AMO/54607 |
|---|---|
| FullText URL | 70_5_425.pdf |
| Author | Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| |
| Abstract | Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer. |
| Keywords | breast cancer phase I trial docetaxel |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 425 |
| End Page | 427 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777441 |
| Web of Science KeyUT | 000388098700018 |
| JaLCDOI | 10.18926/AMO/53675 |
|---|---|
| FullText URL | 69_5_291.pdf |
| Author | Sugiu, Kumi| Iwamoto, Takayuki| Kelly, Catherine M.| Watanabe, Naoki| Motoki, Takayuki| Itoh, Mitsuya| Ohtani, Shoichiro| Higaki, Kenji| Imada, Takako| Yuasa, Takeshi| Omori, Masako| Sonobe, Hiroshi| Fujiwara, Toshiyoshi| Matsuoka, Junji| |
| Abstract | Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies. |
| Keywords | breast cancer neoadjuvant chemotherapy concurrent hormone therapy estrogen receptor positive tumor response |
| Amo Type | Original Article |
| Publication Title | Acta Medica Okayama |
| Published Date | 2015-10 |
| Volume | volume69 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 291 |
| End Page | 299 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2015 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 26490026 |
| Web of Science KeyUT | 000365519600005 |
| JaLCDOI | 10.18926/AMO/53023 |
|---|---|
| FullText URL | 68_6_339.pdf |
| Author | Nishie, Hiroyuki| Mizobuchi, Satoshi| Suzuki, Etsuji| Sato, Kenji| Toda, Yuichiro| Matsuoka, Junji| Morimatsu, Hiroshi| |
| Abstract | The main purpose of this study was to determine the relationships between Japanese individualsʼ interest in living wills and their preferred end-of-life care and death locations. Questionnaires were mailed to 1,000 individuals aged ｧ50 to measure these 2 factors. We examined the associations between the respondentsʼ characteristics and their preferred care and death locations by using multinomial logistic regression models. The response rate was 74%. Home was the most frequently preferred place for end-of-life care (64%), and a palliative care unit (PCU) was the most commonly preferred place to die (51%). Living will interest was associated with a preference for care (odds ratio [OR] 4.74, 95% confidence interval [CI] 1.95-12.1) and death (OR 2.75, 95% CI 1.70-4.47) in a PCU rather than a hospital, but it was not associated with the choice between receiving care or dying at home instead of a hospital. We must consider why Japanese people think home death is impracticable. The Japanese palliative care system should be expanded to meet patientsʼ end-of-life needs, and this includes not only facilitating home care but also increasing access to PCU care. |
| Keywords | advance healthcare directive living will end-of-life care palliative care unit place of death |
| Amo Type | Original Article |
| Publication Title | Acta Medica Okayama |
| Published Date | 2014-12 |
| Volume | volume68 |
| Issue | issue6 |
| Publisher | Okayama University Medical School |
| Start Page | 339 |
| End Page | 348 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2014 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 25519028 |
| Web of Science KeyUT | 000346882200004 |
| Related Url | http://ousar.lib.okayama-u.ac.jp/metadata/53134 |
| Author | Mizoo, Taeko| Taira, Naruto| Nishiyama, Keiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Shien, Tadahiko| Matsuoka, Junji| Doihara, Hiroyoshi| Ishihara, Setsuko| Kawai, Hiroshi| Kawasaki, Kensuke| Ishibe, Youichi| Ogasawara, Yutaka| Komoike, Yoshifumi| Miyoshi, Shinichiro| |
|---|---|
| Published Date | 2013-12-01 |
| Publication Title | BMC Cancer |
| Volume | volume13 |
| Content Type | Journal Article |
| Author | Arata, T| Okitsu, T| Fukazawa, T| Ikeda, H| Kobayashi, K| Yong, C| Kosaka, Y| Narushima, M| Matsuoka, J| Yamamoto, I| Tanaka, N| Lakey, JRT| Kobayashi, N| |
|---|---|
| Published Date | 2004-06 |
| Publication Title | Artificial Organs |
| Volume | volume28 |
| Issue | issue6 |
| Content Type | Journal Article |
| Author | Itoh, Mitsuya| Iwamoto, Takayuki| Matsuoka, Junji| Nogami, Tomohiro| Motoki, Takayuki| Shien, Tadahiko| Taira, Naruto| Niikura, Naoki| Hayashi, Naoki| Ohtani, Shoichiro| Higaki, Kenji| Fujiwara, Toshiyoshi| Doihara, Hiroyoshi| Symmans, W. Fraser| Pusztai, Lajos| |
|---|---|
| Published Date | 2014-01 |
| Publication Title | Breast Cancer Research and Treatment |
| Volume | volume143 |
| Issue | issue2 |
| Content Type | Journal Article |
| Title Alternative | Treatment for a non-compliant patient with cancer and epilepsy |
|---|---|
| FullText URL | 126_133.pdf |
| Author | Minami, Daisuke| Ichihara, Eiki| Okabe, Nobuyuki| Yokomichi, Naosuke| Kouge, Noriko| Kajizono, Makoto| Akimoto, Yutaka| Hori, Keisuke| Matsubara, Minoru| Nasu, Junichiro| Tanimoto, Mitsune| Kiura, Katsuyuki| Matsuoka, Junzi| |
| Abstract | A 58-year-old man with cervical esophageal cancer and a history of epilepsy was treated with chemoradiotherapy from May of 2013. When tube feeding was initiated due to aspiration pneumonitis, the patient showed a degree of irritability that affected routine staff work and treatment compliance. We attempted to perform supportive care for maladjustment by the notice, the fast, and the tube feeding, but there was no improvement. After we added carbamazepine, primidone, and propericiazine (which had been canceled at the initiation of the tube feeding) to the patient's intravenous phenytoin, the symptoms and treatment compliance improved significantly. We concluded that the causes of the patient's irritability were maladjustment and his epilepsy. |
| Keywords | てんかん（epilepsy） 易怒性（irritability） 適応障害（maladjustment） |
| Publication Title | 岡山医学会雑誌 |
| Published Date | 2014-08-01 |
| Volume | volume126 |
| Issue | issue2 |
| Start Page | 133 |
| End Page | 135 |
| ISSN | 0030-1558 |
| language | Japanese |
| Copyright Holders | Copyright (c) 2014 岡山医学会 |
| File Version | publisher |
| DOI | 10.4044/joma.126.133 |
| NAID | 130004685264 |
| Title Alternative | Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer |
|---|---|
| FullText URL | 126_25.pdf |
| Author | Mizoo, Taeko| Shien, Tadahiko| Ito, Maiko| Nogami, Tomohiro| Iwamoto, Takayuki| Motoki, Takayuki| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| |
| Abstract | Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay. Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection. Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected. Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery. |
| Keywords | OSNA法（OSNA method） センチネルリンパ節（sentinel lymph node） micrometastases CK-19 |
| Publication Title | 岡山医学会雑誌 |
| Published Date | 2014-04-01 |
| Volume | volume126 |
| Issue | issue1 |
| Start Page | 25 |
| End Page | 30 |
| ISSN | 0030-1558 |
| Related Url | http://www.okayama-u.ac.jp/user/oma/ |
| language | Japanese |
| Copyright Holders | Copyright (c) 2014 岡山医学会 |
| File Version | publisher |
| DOI | 10.4044/joma.126.25 |
| Author | Matsuoka, Junji| |
|---|---|
| Published Date | 2012-12-03 |
| Publication Title | 岡山医学会雑誌 |
| Volume | volume124 |
| Issue | issue3 |
| Content Type | Article |
| Author | Imada, Takako| Matsuoka, Junji| Motoki, Takayuki| Iwamoto, Takayuki| Oomori, Masako| Iha, Sigemichi| Hongo, Toshie| Henmi, Noriko| Makabe, Mikio| Nogami, Hiromi| |
|---|---|
| Published Date | 2012-12-03 |
| Publication Title | 岡山医学会雑誌 |
| Volume | volume124 |
| Issue | issue3 |
| Content Type | Journal Article |
